Page 118 - GPD-3-3

Gene & Protein in Disease Exploring serum inflammatory biomarkers in GBM

92. Tomolonis JA, Xu X, Dholakia KH, et al. Interaction between with colorectal cancer. Int J Mol Sci. 2023;24(7):6753.
tumor cell TNFR2 and monocyte membrane-bound TNF-α doi: 10.3390/ijms24076753
triggers tumorigenic inflammation in neuroblastoma.
J Immunother Cancer. 2023;11(3):e005478. 96. Vainer N, Dehlendorff C, Johansen J. Systematic literature
review of IL-6 as a biomarker or treatment target in patients
doi: 10.1136/jitc-2022-005478 with gastric, bile duct, pancreatic and colorectal cancer.
93. Hagi T, Nakamura T, Iino T, et al. The diagnostic and Oncotarget. 2018;9:29820-29841.
prognostic value of interleukin-6 in patients with soft tissue doi: 10.18632/oncotarget.25661
sarcomas. Sci Rep. 2017;7(1):9640.
97. Cheng VWT, de Pennington N, Zakaria R, et al. VCAM-
doi: 10.1038/s41598-017-08781-6 1-targeted MRI improves detection of the tumor-brain
94. Steel DM, Whitehead AS. The major acute phase reactants: interface. Clin Cancer Res. 2022;28(11):2385-2396.
C-reactive protein, serum amyloid P component and serum doi: 10.1158/1078-0432.Ccr-21-4011
amyloid A protein. Immunol Today. 1994;15(2):81-88.
98. Han Z, Xiao Z, Kalantar-Zadeh K, et al. Validation of a
doi: 10.1016/0167-5699(94)90138-4 novel modified aptamer-based array proteomic platform in
patients with end-stage renal disease. Diagnostics (Basel).
95. Lehtomäki K, Heervä E, Kellokumpu-Lehtinen PL, et al.
Transient changes in serum CEA, CA19-9, CRP, YKL-40, and 2018;8(4):71.
IL-6 during adjuvant chemotherapy and survival of patients doi: 10.3390/diagnostics8040071

Volume 3 Issue 3 (2024) 18 doi: 10.36922/gpd.3580